Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma

Exclusion Criteria

• •1. Prior radiotherapy or chemotherapy for the treatment of glioma.
• •2. Less than 5 years prior to any invasive neoplasia. Accepted carcinoma in situ of cervix carcinoma or cutaneous vasocelular.
• •3. Cerebral hemorrhage after biopsy.
• •4. Pregnancy or lactation.
• •5. Clinically significant cardiovascular disease: - Myocardial infarction or unstable angina (≤ 6 months before randomization) - Congestive heart failure (CHF) class ≥ II NYHA, New York Heart Association. - Cardiac Arrhythmia uncontrolled despite medication (may include patients with atrial fibrillation often controlled). - Peripheral vascular disease ≥ grade 3 (ie, symptomatic and interfering with everyday activities or specifying repairs or review).
• •6. Continued use of aspirin\> 325 mg / day, currently or recently (within the 10 days prior to randomization).
• •7. Currently established treatment with therapeutic doses of anticoagulants Coumarin derivatives (courmarina, warfarin) or a week before starting treatment. It allows the administration of heparin for control of Deep Vein Thrombosis (DVT)
• •8. Patients with PTSD and patients with inflammatory bowel disease, with risk of perforation.
• •9. HT with values above 150 mmHg systolic pressure of 100 mmHg and diastolic tension is not controllable with standard antihypertensive drugs.
• •10. Not healed scars, ulcers or recent bone fracture.
• •11. Bleeding diathesis or coagulopathy.